Background Despite the well‐defined role of minimal residual disease (MRD) monitoring by
real‐time quantitative polymerase chain reaction (RT‐PCR) for RUNX1/RUNX1T1 and …

Pretransplant measurable residual disease (MRD) has been shown to be associated with
relapse incidence following allogeneic hematopoietic cell transplantation (HCT) for acute …

Core-binding factor acute myeloid leukemia is characterized by t (8; 21) or inv (16) and the
fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11. International guidelines recommend …

The clinical value of serial minimal residual disease (MRD) monitoring in core binding factor
(CBF) acute myeloid leukemia (AML) by quantitative RT-PCR was prospectively assessed in …

DNA sequencing-based measurable residual disease (MRD) detection has shown to be
clinically relevant in AML. However, the same methodology cannot be applied to fusion …

Abstract Recurrent translocations, t (8; 21) or inv (16), in core binding factor acute myeloid
leukemia (CBF‐AML) are amenable to monitoring for minimal residual disease (MRD) with …

Background Posttherapy measurable residual disease (MRD) positivity in core binding
factor acute myeloid leukemia (CBF‐AML) is associated with shorter relapse‐free survival …

Core-binding factor acute myeloid leukemia (CBF-AML) represents 12–15% of all AML
cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains …

Measurable residual disease (MRD) response during acute myeloid leukemia (AML)
treatment is a gold standard for determining treatment strategy, especially in core-binding …

Objectives: To examine the value of minimal residual disease (MRD) by multiparameter flow
cytometry (MFC) in core binding factor (CBF) acute myeloid leukemia (AML). Methods: We …